Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $280.00 at JPMorgan Chase & Co.

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target upped by JPMorgan Chase & Co. from $272.00 to $280.00 in a research note issued to investors on Tuesday,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the biopharmaceutical company’s stock.

ALNY has been the subject of a number of other reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $310.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. HC Wainwright lifted their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Monday, February 24th. Morgan Stanley lifted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Chardan Capital restated a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Finally, Canaccord Genuity Group lifted their price objective on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $304.26.

Alnylam Pharmaceuticals Stock Up 2.4 %

ALNY stock opened at $238.74 on Tuesday. The firm has a 50 day moving average of $254.64 and a 200 day moving average of $260.93. The stock has a market capitalization of $30.91 billion, a PE ratio of -110.02 and a beta of 0.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Sell-side analysts forecast that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In other news, CMO Pushkal Garg sold 1,752 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $251.00, for a total transaction of $439,752.00. Following the completion of the sale, the chief marketing officer now owns 15,705 shares of the company’s stock, valued at $3,941,955. This represents a 10.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jeffrey V. Poulton sold 967 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the sale, the chief financial officer now directly owns 32,786 shares of the company’s stock, valued at $8,366,003.62. The trade was a 2.86 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,986 shares of company stock valued at $20,397,849. 1.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Large investors have recently modified their holdings of the business. Huntington National Bank grew its holdings in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 45 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 73 shares in the last quarter. Park Square Financial Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $28,000. R Squared Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $33,000. Finally, OFI Invest Asset Management acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $35,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.